Skip to content

Becton Dickinson & Co

NYSE: BDX · USD

Becton Dickinson & Co revenue93

Quarterly and annual revenue from company filings.

Business drivers

Business lines and operating measures.

Medication Delivery Solutions · Operating Segments revenue

Reported quarterly Medication Delivery Solutions · Operating Segments revenue. Quarterly figures · USD

Medication Delivery Solutions · Operating Segments revenue. Reported quarterly Medication Delivery Solutions · Operating Segments revenue. Unit: USD. All reporting dates and source links follow.
Period endedUSDReport
Jun 30, 2026From Apr 1, 20261,164,000,000Filed Aug 6, 2026
Mar 31, 2026From Jan 1, 20261,163,000,000Filed May 7, 2026
Jun 30, 2025From Apr 1, 20251,132,000,000Filed Aug 6, 2026
Mar 31, 2025From Jan 1, 20251,117,000,000Filed May 7, 2026

Medication Management Solutions · Operating Segments revenue

Reported quarterly Medication Management Solutions · Operating Segments revenue. Quarterly figures · USD

Medication Management Solutions · Operating Segments revenue. Reported quarterly Medication Management Solutions · Operating Segments revenue. Unit: USD. All reporting dates and source links follow.
Period endedUSDReport
Jun 30, 2026From Apr 1, 2026915,000,000Filed Aug 6, 2026
Mar 31, 2026From Jan 1, 2026829,000,000Filed May 7, 2026
Jun 30, 2025From Apr 1, 2025888,000,000Filed Aug 6, 2026
Mar 31, 2025From Jan 1, 2025811,000,000Filed May 7, 2026

BioPharma Systems · Operating Segments revenue

Reported quarterly BioPharma Systems · Operating Segments revenue. Quarterly figures · USD

BioPharma Systems · Operating Segments revenue. Reported quarterly BioPharma Systems · Operating Segments revenue. Unit: USD. All reporting dates and source links follow.
Period endedUSDReport
Jun 30, 2026From Apr 1, 2026670,000,000Filed Aug 6, 2026
Mar 31, 2026From Jan 1, 2026590,000,000Filed May 7, 2026
Jun 30, 2025From Apr 1, 2025629,000,000Filed Aug 6, 2026
Mar 31, 2025From Jan 1, 2025575,000,000Filed May 7, 2026

Independent series; they may overlap and do not form an additive breakdown.

  • Selected disclosures measure business activity through sales; no operating-volume measures are supplied.
  • The selection is not a complete company breakdown.

Products & projects

BD Alaris™ Infusion System

As previously disclosed, on July 21, 2023, BD received 510(k) clearance from the FDA for its updated BD Alaris™ Infusion System, which enabled both remediation and a return to market for the BD Alaris™ Infusion System.

Filed · source for BD Alaris™ Infusion System

Revenue history

USD millions · Fiscal periods
Jun 30, 2009 through Jun 30, 2026

Quarterly data

Becton Dickinson & Co quarterly financial data in USD millions. FY denotes the company's fiscal year. YTD covers reported quarters only.
Fiscal quarterEndedTotal revenueUSD millions
FY 2026 Q3Jun 30, 20264,983, +5.7% versus FY 2026 Q2
FY 2026 Q2Mar 31, 20264,714, −10.2% versus FY 2026 Q1
FY 2026 Q1Dec 31, 20255,252, −10.8% versus FY 2025 Q4
FY 2025 Q4Sep 30, 20255,891, +6.9% versus FY 2025 Q3
FY 2025 Q3Jun 30, 20255,509, +4.5% versus FY 2025 Q2
FY 2025 Q2Mar 31, 20255,272, +2.0% versus FY 2025 Q1
FY 2025 Q1Dec 31, 20245,168, −4.9% versus FY 2024 Q4
FY 2024 Q4Sep 30, 20245,437, +9.0% versus FY 2024 Q3
FY 2024 Q3Jun 30, 20244,990, −1.1% versus FY 2024 Q2
FY 2024 Q2Mar 31, 20245,045, +7.2% versus FY 2024 Q1
FY 2024 Q1Dec 31, 20234,706, −7.5% versus FY 2023 Q4
FY 2023 Q4Sep 30, 20235,087, +4.3% versus FY 2023 Q3
FY 2023 Q3Jun 30, 20234,878, +1.2% versus FY 2023 Q2
FY 2023 Q2Mar 31, 20234,821, +5.1% versus FY 2023 Q1
FY 2023 Q1Dec 31, 20224,586, −3.7% versus FY 2022 Q4
FY 2022 Q4Sep 30, 20224,761, +2.6% versus FY 2022 Q3
FY 2022 Q3Jun 30, 20224,641, −7.4% versus FY 2022 Q2
FY 2022 Q2Mar 31, 20225,011, +0.3% versus FY 2022 Q1
FY 2022 Q1Dec 31, 20214,995, −2.7% versus FY 2021 Q4
FY 2021 Q4Sep 30, 20215,135, +5.0% versus FY 2021 Q3
FY 2021 Q3Jun 30, 20214,890, −0.3% versus FY 2021 Q2
FY 2021 Q2Mar 31, 20214,907, −7.7% versus FY 2021 Q1
FY 2021 Q1Dec 31, 20205,315, +11.1% versus FY 2020 Q4
FY 2020 Q4Sep 30, 20204,784, +24.1% versus FY 2020 Q3
FY 2020 Q3Jun 30, 20203,855, −9.4% versus FY 2020 Q2
FY 2020 Q2Mar 31, 20204,253, +0.7% versus FY 2020 Q1
FY 2020 Q1Dec 31, 20194,225, −7.8% versus FY 2019 Q4
FY 2019 Q4Sep 30, 20194,584, +5.4% versus FY 2019 Q3
FY 2019 Q3Jun 30, 20194,350, +3.7% versus FY 2019 Q2
FY 2019 Q2Mar 31, 20194,195, +0.8% versus FY 2019 Q1
FY 2019 Q1Dec 31, 20184,160, −5.5% versus FY 2018 Q4
FY 2018 Q4Sep 30, 20184,402, +2.9% versus FY 2018 Q3
FY 2018 Q3Jun 30, 20184,278, +1.3% versus FY 2018 Q2
FY 2018 Q2Mar 31, 20184,222, +37.1% versus FY 2018 Q1
FY 2018 Q1Dec 31, 20173,080, −2.7% versus FY 2017 Q4
FY 2017 Q4Sep 30, 20173,166, +4.3% versus FY 2017 Q3
FY 2017 Q3Jun 30, 20173,035, +2.2% versus FY 2017 Q2
FY 2017 Q2Mar 31, 20172,969, +1.6% versus FY 2017 Q1
FY 2017 Q1Dec 31, 20162,922, −9.6% versus FY 2016 Q4
FY 2016 Q4Sep 30, 20163,231, +1.0% versus FY 2016 Q3
FY 2016 Q3Jun 30, 20163,198, +4.3% versus FY 2016 Q2
FY 2016 Q2Mar 31, 20163,067, +2.7% versus FY 2016 Q1
FY 2016 Q1Dec 31, 20152,986, −2.4% versus FY 2015 Q4
FY 2015 Q4Sep 30, 20153,059, −2.0% versus FY 2015 Q3
FY 2015 Q3Jun 30, 20153,120, +52.1% versus FY 2015 Q2
FY 2015 Q2Mar 31, 20152,051, 0.0% versus FY 2015 Q1
FY 2015 Q1Dec 31, 20142,051, −6.9% versus FY 2014 Q4
FY 2014 Q4Sep 30, 20142,202, +2.1% versus FY 2014 Q3
FY 2014 Q3Jun 30, 20142,157, +4.1% versus FY 2014 Q2
FY 2014 Q2Mar 31, 20142,072, +2.8% versus FY 2014 Q1
FY 2014 Q1Dec 31, 20132,015, −4.1% versus FY 2013 Q4
FY 2013 Q4Sep 30, 20132,100.768, +2.3% versus FY 2013 Q3
FY 2013 Q3Jun 30, 20132,052.664, +2.6% versus FY 2013 Q2
FY 2013 Q2Mar 31, 20132,000.375, +5.3% versus FY 2013 Q1
FY 2013 Q1Dec 31, 20121,900.192, −3.4% versus FY 2012 Q4
FY 2012 Q4Sep 30, 20121,967.171, −0.7% versus FY 2012 Q3
FY 2012 Q3Jun 30, 20121,980.53, −0.5% versus FY 2012 Q2
FY 2012 Q2Mar 31, 20121,990.818, +5.5% versus FY 2012 Q1
FY 2012 Q1Dec 31, 20111,887.645, −8.0% versus FY 2011 Q4
FY 2011 Q4Sep 30, 20112,050.795, +1.8% versus FY 2011 Q3
FY 2011 Q3Jun 30, 20112,014.081, +4.8% versus FY 2011 Q2
FY 2011 Q2Mar 31, 20111,922.023, +4.3% versus FY 2011 Q1
FY 2011 Q1Dec 31, 20101,842.005, +6.3% versus FY 2010 Q4
FY 2010 Q4Sep 30, 20101,732.476, −7.8% versus FY 2010 Q3
FY 2010 Q3Jun 30, 20101,878.229, +1.8% versus FY 2010 Q2
FY 2010 Q2Mar 31, 20101,844.854, −3.8% versus FY 2010 Q1
FY 2010 Q1Dec 31, 20091,916.774, +1.0% versus FY 2009 Q4
FY 2009 Q4Sep 30, 20091,897.733, +4.3% versus FY 2009 Q3
FY 2009 Q3Jun 30, 20091,820.255, Change unavailable versus FY 2009 Q2
Sources and definitions

Figures from official company filings and financial reports, in the reported currency. FY identifies the fiscal year; the end date identifies the calendar period. Last checked Oct 19, 2026.

Annual values come from annual filings. Historical quarters retain their reporting basis; rounding and reclassifications can make their sum differ from the annual figure. YTD sums the available fiscal quarters and compares the same quarters of the previous fiscal year.

Missing values are shown as unavailable. Fourth quarters use reported values where available, otherwise the annual amount less the matching nine-month amount.

Total revenue
Reported consolidated revenue from the issuer filing. Each observation identifies its accounting concept; bank net revenue is net of interest expense when that concept is reported.
Annual and quarterly differences
  • FY 2012 · Total revenue: annual 7,708.382, quarter sum 7,826.164 USD millions.
  • FY 2013 · Total revenue: annual 8,054, quarter sum 8,053.999 USD millions.
  • FY 2015 · Total revenue: annual 10,282, quarter sum 10,281 USD millions.
  • FY 2016 · Total revenue: annual 12,483, quarter sum 12,482 USD millions.
  • FY 2017 · Total revenue: annual 12,093, quarter sum 12,092 USD millions.
  • FY 2018 · Total revenue: annual 15,983, quarter sum 15,982 USD millions.
  • FY 2019 · Total revenue: annual 17,290, quarter sum 17,289 USD millions.
  • FY 2021 · Total revenue: annual 20,248, quarter sum 20,247 USD millions.
  • FY 2022 · Total revenue: annual 18,870, quarter sum 19,408 USD millions.